A Retrospective Study On Shengqing Jiangzhuo Capsule In Treating Diabetic Kidney Disease(G3a-G5 Stage)

ObjectiveDiabetic kidney disease(DKD)is one of the major chronic complications of diabetes,which is the leading cause of global end-stage kidney disease(ESKD),forcing a serious threat to public health.For DKD patients with renal insufficiency,treatment is very limited.This is a single center,retrospective,observational study.By analyzing the effect of Shengqing Jiangzhuo capsule(SQ)on creatinine level in hospitalized patients with DKD complicated with CKD 3-5,it provides a basis for its clinical application.MethodsIn this single-center,retrospective,observational study,the clinical information of DKD patients with renal insufficiency hospitalized in nephrology department from 2018 to 2019 was extracted by Hospital Information System(HIS).The patients were divided into the treatment group and the control group according to whether they were treated with SQ.The endpoint was the change in serum creatinine(Scr),urea(Urea)and fasting plasma glucose(FPG)from baseline to discharge.Dependent sample t test and Mann-Whitney test were used to compare the difference of endpoint between the treatment group and the control group to evaluate the efficacy of SQ.CKD stage,ACR stage,BMI,smoking history,whether combined use of drugs(TCM decoction,TCM retention enema,Shenkang preparation,insulin,etc.)were divided into different subgroups to analyze the efficacy of SQ.ResultsA total of 127 patients(92 in the treatment group and 35 in the control group)were enrolled in this study.The median length of hospital stay was9.2 days,with an average age of 62.2 years,with 72.4%males and an average e GFR of 22.6 ml/min/1.73 m~2.The median difference of Scr was 9.5μmol/L in the treatment group and-1μmol/L in the control group,the difference was statistically significant(P=0.006).The median difference of FPG was-0.4mmol/L in the treatment group and 0.6 mmol/L in the control group,the difference was not statistically significant(P=0.199).Subgroup analysis of CKD stage showed that there was no significant difference in Scr difference between the treatment group and the control group before and after treatment(CKD stage 3:P=0.442;CKD stage 4:P=0.321;CKD stage 5:P=0.147).In the sub-groups without smoking history,BMI<25 kg/m~2,ACR>300 mg/g,and without other creatinine-lowering drugs(TCM decoction,TCM retention enema,and Shenkang preparation),the difference in Scr between the two groups before and after treatment was statistically significant.ConclusionShengqing Jiangzhuo capsule had no significant effect on the improvement of renal function in patients with DKD complicated with renal insufficiency in the short term,but the decline trend of creatinine in the treatment group suggested potential benefits,especially in patients without smoking history,BMI<25 kg/m~2,ACR>300 mg/g,and did not cause the increase of serum potassium.